Am­gen to set­tle case over drug mar­ket­ing

Austin American-Statesman - - BUSINESS -

Am­gen Inc. has agreed to pay $762 mil­lion to re­solve fed­eral lit­i­ga­tion ac­cus­ing the drug­maker of mar­ket­ing the ane­mia treat­ment Aranesp for un­ap­proved uses.

The Thou­sand Oaks, Calif., com­pany pleaded guilty Tues­day to il­le­gally in­tro­duc­ing a mis­branded drug into in­ter­state com­merce and will pay a $136 mil­lion fine and a $14 mil­lion for­fei­ture, ac­cord­ing to the U.S. At­tor­ney’s Of­fice for the East­ern District of New York.

It also agreed to a $612 mil­lion civil set­tle­ment, ac­cord­ing to a law firm con­nected to the case.

The U.S. at­tor­ney’s of­fice de­clined to com­ment on that be­cause the civil set­tle­ment won’t be un­sealed un­til a Wed­nes­day court hear­ing, when a fed­eral judge also will de­cide whether to ac­cept the plea and sen­tence in the crim­i­nal case.

Am­gen de­vel­ops bi­o­logic medicines, or drugs pro­duced by liv­ing cells rather than by mix­ing chem­i­cals. Aranesp is ap­proved for treat­ing pa­tients with ane­mia caused by chronic re­nal fail­ure and chemo­ther­apy.

Newspapers in English

Newspapers from USA

© PressReader. All rights reserved.